1448 completed, 567 unknown, 549 recruiting, 422 terminated. 1355 Phase 2, 1111 Phase 1, 498 Not applicable, 312 Phase 3, 125 Phase 4.
Follow Recurrence: new trials by email Literature Review of Recurrence trials Research Report on Recurrence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Excyte Biopharma Ltd | 64 | 2027-12-01 | 2026-11-06 |
| Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal | Phase 1 / Phase 2 | Not yet recruiting | Clive Michelsen | 60 | 2027-07-01 | 2026-10-13 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Better Care Closer to Home: Enhancing Primary and Community Care Path Active™, a smart insole system designed to reduce the risk of plantar ulceration in patients with diabetic foot disease - Diabetic Foot Disease, Recurrence | Not applicable | Not yet recruiting | Universidad Complutense de Madrid | 84 | 2027-04-01 | 2026-11-03 |
| Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL) Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Recruiting | Sunil G. Iyer | 45 | 2027-03-31 | 2026-11-13 |
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT LX-101 - Ewing Sarcoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 120 | 2027-02-01 | 2026-08-24 |
| Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy) - Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis) | Phase 4 | Not yet recruiting | University Hospital, Toulouse | 30 | 2027-02-01 | 2026-11-05 |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP) | Phase 1 | Not yet recruiting | RiboX Therapeutics Ltd. | 27 | 2027-02-01 | 2026-10-28 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 25 | 2027-01-01 | 2026-11-03 |
| A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia CAV - Acute Myeloid Leukemia (AML) | Phase 2 | Not yet recruiting | University of Rochester | 24 | 2026-12-31 | 2026-10-16 |
| Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 40 | 2026-12-31 | 2026-10-28 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 300 | 2026-12-30 | 2026-11-12 |
| IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia IASO206 injection - Autoimmune Hemolytic Anemia, Relapsed/Refractory | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-12-15 | 2026-11-05 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. GNTbm-38 - Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Not yet recruiting | Great Novel Therapeutics Biotech & Medicals Corporation | 70 | 2026-12-01 | 2026-09-25 |
Showing 20 of 3569. Sign in to see all of them.
Multiple Myeloma (401) · Leukemia, Myeloid, Acute (321) · Lymphoma (284) · Neoplasms (275) · Neoplasm Metastasis (258) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (251) · Lymphoma, Non-Hodgkin (244) · Lymphoma, Large B-Cell, Diffuse (239) · Leukemia, Lymphocytic, Chronic, B-Cell (211) · Leukemia (201) · Burkitt Lymphoma (190) · Hodgkin Disease (175) · Lymphoma, Follicular (169) · Lymphoma, Mantle-Cell (166)
Pathological Conditions, Signs and Symptoms (3569) · Pathologic Processes (3564) · Disease Attributes (3563) · Neoplasms (2245) · Neoplasms by Histologic Type (1898) · Hemic and Lymphatic Diseases (1438) · Immune System Diseases (1295) · Immunoproliferative Disorders (1149) · Lymphoproliferative Disorders (1145) · Neoplasms by Site (1001) · Hematologic Diseases (968) · Lymphatic Diseases (874) · Cardiovascular Diseases (535) · Neoplasms, Glandular and Epithelial (516) · Vascular Diseases (500)
Cyclophosphamide (170) · Dexamethasone (151) · Rituximab (101) · fludarabine (97) · Cytarabine (81) · Lenalidomide (79) · Gemcitabine (68) · Bortezomib (67) · fludarabine phosphate (65) · venetoclax (60) · Etoposide (59) · pembrolizumab (55) · pomalidomide (55) · Carboplatin (50) · Paclitaxel (50)
M.D. Anderson Cancer Center (62) · Celgene (53) · Novartis Pharmaceuticals (50) · Memorial Sloan Kettering Cancer Center (48) · National Cancer Institute (NCI) (39) · Sun Yat-sen University (36) · Fred Hutchinson Cancer Center (31) · AbbVie (27) · Assistance Publique - Hôpitaux de Paris (25) · Amgen (24) · Institute of Hematology & Blood Diseases Hospital, China (24) · AstraZeneca (23) · Pfizer (22) · Dana-Farber Cancer Institute (20) · H. Lee Moffitt Cancer Center and Research Institute (20)
United States (1455) · China (688) · France (389) · Spain (304) · Canada (295) · Italy (290) · Germany (285) · United Kingdom (220) · Australia (197) · South Korea (173) · Belgium (158) · Netherlands (130) · Japan (117) · Poland (114) · Taiwan (110)
Alison Moskowitz, MD (5) · Brenda Sandmaier (5)
PMID 34515338, PMID 32499241, PMID 41671463, PMID 26932146, PMID 30918100, PMID 31039052, PMID 31401903, PMID 32426039, PMID 35622074, PMID 22067384, PMID 22980441, PMID 23054212, PMID 23306310, PMID 24131282, PMID 24378877, PMID 24844673, PMID 26526385, PMID 26706103, PMID 27733070, PMID 28188133, PMID 28751099, PMID 28751558, PMID 28770420, PMID 29477379, PMID 29673108, PMID 31685558, PMID 32757523, PMID 33674274, PMID 33676197, PMID 33820822, PMID 34398557, PMID 34498507, PMID 34702811, PMID 35266417, PMID 35397664, PMID 35422096, PMID 35772429, PMID 35978286, PMID 36100310, PMID 36718018, PMID 37061656, PMID 37142273, PMID 37185961, PMID 37341961, PMID 37393120, PMID 37606897, PMID 38092009, PMID 38190117, PMID 38502198, PMID 39018512
2023 (49), 2015 (24), 2017 (20), 2018 (20), 2019 (19), 2016 (18), 2025 (16), 2009 (15), 2014 (15), P30CA015704 (13), 2008 (10), U01CA097452 (9), P30CA006973 (6), P30CA016672 (6), P30CA043703 (6)